Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative MRD-guided adebrelimab-based immunotherapy in stage II–III NSCLC
ChiCTR2600118144Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: 2-year event-free survival rate. Started Feb 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600118144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118144.